Table 2.
Base-case results: observed and projected pneumococcal disease cases with and without a PCV IIP, 2005–2015
| Parameter | With PCV IIP | Without PCV IIP | Incremental |
|---|---|---|---|
| Outcomes | |||
| Cases of: | |||
| Bacteremia | 26,492 | 40,020 | − 13,528 |
| Meningitis | 2864 | 4326 | − 1462 |
| Non-hospitalized pneumonia | 1,765,364 | 2,448,240 | − 682,876 |
| Hospitalized pneumonia | 690,705 | 743,529 | − 52,824 |
| AOM | 12,218,367 | 15,916,360 | − 3,697,993 |
| Deaths | 80,762 | 87,393 | − 6631 |
| Among those < 5 years | 755 | 1008 | − 253 |
| Among those > 5 years | 80,007 | 86,385 | − 6377 |
| Costs (in $ millions) | |||
| Direct medical costs | $11,001.2 | $11,770.8 | − $769.5 |
| Vaccine-related costs | $833.9 | $0.0 | $833.9 |
| IPD costs | $810.3 | $1200.8 | − $390.5 |
| Pneumonia costs | $7286.0 | $7872.0 | − $586.0 |
| AOM costs | $2071.1 | $2697.9 | − $626.8 |
| Indirect costs | $4070.6 | $5061.1 | − $990.5 |
| Total costs | $15,071.9 | $16,831.9 | − $1760.0 |
AOM acute otitis media, IIP infant immunization program, IPD invasive pneumococcal disease, PCV pneumococcal conjugate vaccine
Costs presented in 2018 Canadian dollars